These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 23716037

  • 1. Effect of the cathepsin K inhibitor odanacatib administered once weekly on bone mineral density in Japanese patients with osteoporosis--a double-blind, randomized, dose-finding study.
    Nakamura T, Shiraki M, Fukunaga M, Tomomitsu T, Santora AC, Tsai R, Fujimoto G, Nakagomi M, Tsubouchi H, Rosenberg E, Uchida S.
    Osteoporos Int; 2014 Jan; 25(1):367-76. PubMed ID: 23716037
    [Abstract] [Full Text] [Related]

  • 2. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density.
    Bone HG, McClung MR, Roux C, Recker RR, Eisman JA, Verbruggen N, Hustad CM, DaSilva C, Santora AC, Ince BA.
    J Bone Miner Res; 2010 May; 25(5):937-47. PubMed ID: 19874198
    [Abstract] [Full Text] [Related]

  • 3. Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial.
    Bone HG, Dempster DW, Eisman JA, Greenspan SL, McClung MR, Nakamura T, Papapoulos S, Shih WJ, Rybak-Feiglin A, Santora AC, Verbruggen N, Leung AT, Lombardi A.
    Osteoporos Int; 2015 Feb; 26(2):699-712. PubMed ID: 25432773
    [Abstract] [Full Text] [Related]

  • 4. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
    McClung MR, O'Donoghue ML, Papapoulos SE, Bone H, Langdahl B, Saag KG, Reid IR, Kiel DP, Cavallari I, Bonaca MP, Wiviott SD, de Villiers T, Ling X, Lippuner K, Nakamura T, Reginster JY, Rodriguez-Portales JA, Roux C, Zanchetta J, Zerbini CAF, Park JG, Im K, Cange A, Grip LT, Heyden N, DaSilva C, Cohn D, Massaad R, Scott BB, Verbruggen N, Gurner D, Miller DL, Blair ML, Polis AB, Stoch SA, Santora A, Lombardi A, Leung AT, Kaufman KD, Sabatine MS, LOFT Investigators.
    Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
    [Abstract] [Full Text] [Related]

  • 5. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.
    Bonnick S, De Villiers T, Odio A, Palacios S, Chapurlat R, DaSilva C, Scott BB, Le Bailly De Tilleghem C, Leung AT, Gurner D.
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4727-35. PubMed ID: 24064689
    [Abstract] [Full Text] [Related]

  • 6. Continuous treatment with odanacatib for up to 8 years in postmenopausal women with low bone mineral density: a phase 2 study.
    Rizzoli R, Benhamou CL, Halse J, Miller PD, Reid IR, Rodríguez Portales JA, DaSilva C, Kroon R, Verbruggen N, Leung AT, Gurner D.
    Osteoporos Int; 2016 Jun; 27(6):2099-107. PubMed ID: 26879200
    [Abstract] [Full Text] [Related]

  • 7. Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial.
    Brixen K, Chapurlat R, Cheung AM, Keaveny TM, Fuerst T, Engelke K, Recker R, Dardzinski B, Verbruggen N, Ather S, Rosenberg E, de Papp AE.
    J Clin Endocrinol Metab; 2013 Feb; 98(2):571-80. PubMed ID: 23337728
    [Abstract] [Full Text] [Related]

  • 8. Treatment with zoledronic acid subsequent to odanacatib prevents bone loss in postmenopausal women with osteoporosis.
    Koldkjær Sølling AS, Harsløf T, Langdahl B.
    Osteoporos Int; 2019 May; 30(5):995-1002. PubMed ID: 30656367
    [Abstract] [Full Text] [Related]

  • 9. Potential role of odanacatib in the treatment of osteoporosis.
    Ng KW.
    Clin Interv Aging; 2012 May; 7():235-47. PubMed ID: 22866001
    [Abstract] [Full Text] [Related]

  • 10. Randomized, controlled trial to assess the safety and efficacy of odanacatib in the treatment of men with osteoporosis.
    Binkley N, Orwoll E, Chapurlat R, Langdahl BL, Scott BB, Giezek H, Santora AC.
    Osteoporos Int; 2021 Jan; 32(1):173-184. PubMed ID: 33200257
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
    Emkey R, Delmas PD, Bolognese M, Borges JL, Cosman F, Ragi-Eis S, Recknor C, Zerbini CA, Neate C, Sedarati F, Epstein S.
    Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
    [Abstract] [Full Text] [Related]

  • 12. Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study.
    Ishibashi H, Crittenden DB, Miyauchi A, Libanati C, Maddox J, Fan M, Chen L, Grauer A.
    Bone; 2017 Oct; 103():209-215. PubMed ID: 28687496
    [Abstract] [Full Text] [Related]

  • 13. Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis.
    Nakamura T, Matsumoto T, Sugimoto T, Shiraki M.
    Osteoporos Int; 2012 Mar; 23(3):1131-40. PubMed ID: 21927920
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of oral recombinant calcitonin tablets in postmenopausal women with low bone mass and increased fracture risk: a randomized, placebo-controlled trial.
    Binkley N, Bone H, Gilligan JP, Krause DS.
    Osteoporos Int; 2014 Nov; 25(11):2649-56. PubMed ID: 25027109
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data.
    McClung MR, Zanchetta JR, Racewicz A, Roux C, Benhamou CL, Man Z, Eusebio RA, Beary JF, Burgio DE, Matzkin E, Boonen S, Delmas P.
    Osteoporos Int; 2013 Jan; 24(1):293-9. PubMed ID: 22752050
    [Abstract] [Full Text] [Related]

  • 16. Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study.
    Liang BC, Shi ZY, Wang B, Wu P, Kong LC, Yao JL, Li CW, Shi XL.
    Orthop Surg; 2017 Feb; 9(1):103-109. PubMed ID: 28276638
    [Abstract] [Full Text] [Related]

  • 17. A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group).
    Shiraki M, Fukunaga M, Kushida K, Kishimoto H, Taketani Y, Minaguchi H, Inoue T, Morita R, Morii H, Yamamoto K, Ohashi Y, Orimo H.
    Osteoporos Int; 2003 May; 14(3):225-34. PubMed ID: 12730746
    [Abstract] [Full Text] [Related]

  • 18. Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis.
    Stone JA, McCrea JB, Witter R, Zajic S, Stoch SA.
    Br J Clin Pharmacol; 2019 Jun; 85(6):1072-1083. PubMed ID: 30663085
    [Abstract] [Full Text] [Related]

  • 19. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
    Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD.
    J Bone Miner Res; 2009 Apr; 24(4):719-25. PubMed ID: 19049326
    [Abstract] [Full Text] [Related]

  • 20. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect.
    Eisman JA, Bone HG, Hosking DJ, McClung MR, Reid IR, Rizzoli R, Resch H, Verbruggen N, Hustad CM, DaSilva C, Petrovic R, Santora AC, Ince BA, Lombardi A.
    J Bone Miner Res; 2011 Feb; 26(2):242-51. PubMed ID: 20740685
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.